Table III.
Anti-ATBF1 antibody | ||||||||
---|---|---|---|---|---|---|---|---|
MB34 (%) | D1-120 (%) | MB44 (%) | MB49 (%) | |||||
Tubular adenocarcinoma | Nucleus | Cytoplasm | Nucleus | Cytoplasm | Nucleus | Cytoplasm | Nucleus | Cytoplasm |
tub1 | ||||||||
m (n=11) | 0 | 27a | 36 | 18 | 46 | 27 | 0 | 27c |
sm (n=22) | 0 | 63a | 14 | 23 | 45 | 45 | 0 | 59c |
mp (n=5) | 0 | 100a | 80 | 60 | 100 | 60 | 0 | 100c |
tub2 | ||||||||
m (n=2) | 0 | 50 | 0b | 100 | 50 | 50 | 0 | 50 |
sm (n=4) | 0 | 50 | 25b | 50 | 25 | 50 | 0 | 50 |
mp (n=13) | 0 | 100 | 85b | 92 | 92 | 85 | 0 | 100 |
MB34 recognizes the N-terminal region of ATBF1 (amino acids 238-255); D1-120 recognizes the middle region of ATBF1 (amino acids 2,114–2,147); MB44 recognizes the middle region of ATBF1 (amino acids 2,229–2,245); and MB49 recognizes the C-terminal region of ATBF1 (amino acids 3,410–3,426). ATBF1 expression was significantly correlated with the depth of cancer invasion
P=0.004
P=0.004
P=0.006). ATBFT, AT motif binding factor 1; tub1, well-differentiated adenocarcinoma; tub2, moderately differentiated adenocarcinoma; m, mucosa; sm, submucosa; mp, muscularis propria.